Billy......I think Pete provided a very good response to your question.
I would add the following...While its a fair question, I think it would be more appropriate to ask when we have an update on the phase 2 trial results for brilacidin. Hopefully, the update will be very positive and if it is....
I think we will attract significant interest from several BP companies. Right now, there are a number of these BP companies with significant cash positions that are not making them any money and several of them have shrinking drug pipelines which need to be replaced with new drugs or even better new drug platforms. Well, as Pete said, Brilacidin is not a single use drug but a drug with potential of multiple uses. I agree with him that BP companies will want the entire platform.
The question is will they step forward with a total cash purchase or a partial cash purchase buyout combined with their stock. I believe to minimize their risk by reducing the size of their upfront cash payment and/or stock, they would rather have a royalty component based on the revenues generated from Brilacidin. The royalty would probably be at least 20% of revenues but hopefully more like 30 to 40%.
I believe that Leo will want significant cash upfront, probably $1B to $2B to allow him to develop Kevetrin which could be as large as Brilicidin.
The share price.....it will be based on the some multiple of Brilacidin royalty payments and the speculative potential of Kevetrin. I am not going to speculate what those multiples will be but as others have done but I believe they will be LARGE and will allow many shareholders to retire and help many people with their charitable contributions. Like Pete said, IPIX could be a game changer for many people suffering from medical illnesses as well as shareholders.
Newbies.......most of these posts including mine are just opinions...DO YOUR OWN DUE DILIGENCE!!
Anyone who claims all of their comments are pro rated should not be trusted!!
